has provided new ways for the treatment of advanced non-small cell lung cancer. Accurate evaluation of therapeutic efficacy can guide clinical decision making and is critical in the treatment of oncology patients. Positron emission tomography (PET)/computed tomography (CT)
as a non- invasive and high-safety whole-body imaging examination
can provide information on metabolism of primary lesions
lymph nodes and metastasis
and has been widely used in the diagnosis and evaluation of tumor treatment efficacy. Meanwhile
novel targeting agents are gradually entering the clinical trials
which will improve the accuracy of treatment evaluation. This review summarized the clinical application and research progress of PET/CT in evaluating the efficacy of immunotherapy (mainly ICI).
Role of 18 F-FDG PET/CT and novel molecular imaging in guiding tumor immunotherapy
Research progress of neoadjuvant immunotherapy for non-small cell lung cancer and the challenge of evaluating therapeutic response with imaging methods
Evaluation of prostate cancer across different treatment stages using 18F-FDG PET imaging
Advances in the development of TROP2-targeted nuclear medicine molecular imaging probes
The predictive value of CT radiomics model for immunotherapy efficacy in non-small cell lung cancer